Update on oral immunotherapy for egg allergy. Issue 10 (3rd October 2017)

• Record Type: Journal Article
• Authors: Graham, François; Tardio, Natacha; Paradis, Louis; Des Roches, Anne; Bégin, Philippe
• Is Part Of: Human vaccines & immunotherapeutics. Volume 13:Issue 10(2017)
• Page Start: 2452
• Page End: 2461
• Publication Date: 2017-10-03
• Subjects: desensitization -- egg allergy -- food allergy -- OIT -- oral immunotherapy -- ovalbumin -- tolerance -- treatment; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2017.1339844
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: Oral immunotherapy (OIT) is an emerging treatment of IgE-mediated egg allergy. In the past decade, a multitude of studies have assessed the potential for egg OIT to induce clinical desensitization. The following review will evaluate the efficacy and safety of this therapy as determined by randomized controlled, non-randomized controlled and uncontrolled trials. Recent studies using reduced allergenic egg products and anti-IgE assisted therapy to improve egg OIT safety will also be discussed. Recent advances in the mechanisms underlying food OIT suggest that certain immune parameters may be helpful in monitoring response to therapy, including egg OIT. Although, egg OIT is consistently shown to be effective with regards to clinical desensitization, fewer studies have looked at persistent tolerance or sustained unresponsiveness. Limited results of long-term follow-up trials suggest that this therapy may have disease-modifying effects. In general, the comparison of studies is complicated by major differences in study designs, OIT protocols and endpoints.